Monday, Angel Biotechnology Holdings Plc (ABH.L), the biopharmaceutical contract manufacturer, announced the signing of a fourth GMP Manufacturing contract with Materia Medica Holding, a pharmaceutical company in Russia. The contract, valued at circa £1.2 million, is for process development and GMP manufacture of specific antibodies. Over 90% of the value this contract will be invoiced over the next 18 months, the company said.
"Our relationship with Materia Medica continues to grow with the award of this fourth GMP manufacturing contract. We have now been working with Materia Medica for over two years and in that time have worked closely with Materia Medica and the Medicines and Health care products Regulatory Agency or MHRA to forge a clear regulatory path for it's products. Angel has to date contracted work with Materia Medica to a total value of circa £4 million. This is a clear reflection of Materia Medica's confidence in Angel's manufacturing and regulatory capabilities in the advanced biologics arena. We look forward to further contracts in the future to deliver Materia Medica's pipeline of EU licensed products," said Gordon Sherriff, Angel's chief operating officer.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.